These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Luo J; Zha S; Gage WR; Dunn TA; Hicks JL; Bennett CJ; Ewing CM; Platz EA; Ferdinandusse S; Wanders RJ; Trent JM; Isaacs WB; De Marzo AM Cancer Res; 2002 Apr; 62(8):2220-6. PubMed ID: 11956072 [TBL] [Abstract][Full Text] [Related]
3. The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alpha-methylacyl-CoA racemase. Wang J; Weng J; Cai Y; Penland R; Liu M; Ittmann M Prostate; 2006 Jun; 66(8):847-57. PubMed ID: 16491480 [TBL] [Abstract][Full Text] [Related]
4. Group IIA phospholipase A as a prognostic marker in prostate cancer: relevance to clinicopathological variables and disease-specific mortality. Mirtti T; Laine VJ; Hiekkanen H; Hurme S; Rowe O; Nevalainen TJ; Kallajoki M; Alanen K APMIS; 2009 Mar; 117(3):151-61. PubMed ID: 19245588 [TBL] [Abstract][Full Text] [Related]
5. Alpha-methylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer. Ananthanarayanan V; Deaton RJ; Yang XJ; Pins MR; Gann PH Prostate; 2005 Jun; 63(4):341-6. PubMed ID: 15602744 [TBL] [Abstract][Full Text] [Related]
6. Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions. Schostak M; Miller K; Krause H; Schrader M; Kempkensteffen C; Kollermann J Cancer Detect Prev; 2006; 30(5):449-54. PubMed ID: 17067752 [TBL] [Abstract][Full Text] [Related]
7. Differential expression of alpha-methylacyl-coenzyme A racemase in colorectal carcinoma bears clinical and pathologic significance. Lin A; Weiser MR; Klimstra DS; Paty PB; Tang LH; Al-Ahmadie H; Hoo Park S; Guillem JG; Temple L; Wong WD; Gerald WL; Shia J Hum Pathol; 2007 Jun; 38(6):850-6. PubMed ID: 17442371 [TBL] [Abstract][Full Text] [Related]
8. Alpha-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis. Witkiewicz AK; Varambally S; Shen R; Mehra R; Sabel MS; Ghosh D; Chinnaiyan AM; Rubin MA; Kleer CG Cancer Epidemiol Biomarkers Prev; 2005 Jun; 14(6):1418-23. PubMed ID: 15941950 [TBL] [Abstract][Full Text] [Related]
9. Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker. Jiang Z; Wu CL; Woda BA; Iczkowski KA; Chu PG; Tretiakova MS; Young RH; Weiss LM; Blute RD; Brendler CB; Krausz T; Xu JC; Rock KL; Amin MB; Yang XJ Histopathology; 2004 Sep; 45(3):218-25. PubMed ID: 15330799 [TBL] [Abstract][Full Text] [Related]
11. Alpha-methylacyl-CoA racemase (P504S) expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone. Leav I; McNeal JE; Ho SM; Jiang Z Hum Pathol; 2003 Mar; 34(3):228-33. PubMed ID: 12673556 [TBL] [Abstract][Full Text] [Related]
12. Heterogeneous expression of alpha-methylacyl-CoA racemase in prostatic cancer correlates with Gleason score. Murphy AJ; Hughes CA; Lannigan G; Sheils O; O'Leary J; Loftus B Histopathology; 2007 Jan; 50(2):243-51. PubMed ID: 17222253 [TBL] [Abstract][Full Text] [Related]
13. A novel diagnostic test for prostate cancer emerges from the determination of alpha-methylacyl-coenzyme a racemase in prostatic secretions. Zielie PJ; Mobley JA; Ebb RG; Jiang Z; Blute RD; Ho SM J Urol; 2004 Sep; 172(3):1130-3. PubMed ID: 15311056 [TBL] [Abstract][Full Text] [Related]
14. High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer. Box A; Alshalalfa M; Hegazy SA; Donnelly B; Bismar TA Tumour Biol; 2016 Sep; 37(9):12287-12299. PubMed ID: 27271990 [TBL] [Abstract][Full Text] [Related]
15. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. Henshall SM; Horvath LG; Quinn DI; Eggleton SA; Grygiel JJ; Stricker PD; Biankin AV; Kench JG; Sutherland RL J Natl Cancer Inst; 2006 Oct; 98(19):1420-4. PubMed ID: 17018789 [TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of alpha-methylacyl-coA racemase among men with high grade prostatic intraepithelial neoplasia in prostate biopsies. Stewart J; Fleshner N; Cole H; Toi A; Sweet J J Urol; 2008 May; 179(5):1751-5; discussion 1755. PubMed ID: 18343427 [TBL] [Abstract][Full Text] [Related]
17. Sequence variation in alpha-methylacyl-CoA racemase and risk of early-onset and familial prostate cancer. Levin AM; Zuhlke KA; Ray AM; Cooney KA; Douglas JA Prostate; 2007 Oct; 67(14):1507-13. PubMed ID: 17683075 [TBL] [Abstract][Full Text] [Related]
18. Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl CoA racemase (P504S). Jiang Z; Woda BA; Wu CL; Yang XJ Am J Clin Pathol; 2004 Aug; 122(2):275-89. PubMed ID: 15323145 [TBL] [Abstract][Full Text] [Related]
19. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy. Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661 [TBL] [Abstract][Full Text] [Related]
20. Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha methylacyl-CoA racemase (AMACR) in the work-up of prostate cancer. Kunju LP; Chinnaiyan AM; Shah RB Histopathology; 2005 Dec; 47(6):587-96. PubMed ID: 16324196 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]